| iPSC-Derived Dopaminergic Neurons | |
|---|---|
| Lineage | Stem Cell > iPSC > Dopaminergic |
| Markers | TH, SLC6A3, LMX1A, PITX3, FOXA2, EN1 |
| Brain Regions | In Vitro (Midbrain Patterning) |
| Disease Relevance | Parkinson's Disease, Drug Development, Disease Modeling |
| Protocol | Directed Differentiation (14-21 days) |
Ipsc Derived Dopaminergic Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
iPSC-Derived Dopaminergic Neurons are specialized neurons generated from induced pluripotent stem cells (iPSCs) through directed differentiation protocols that recapitulate midbrain development.[1] These cells express key dopaminergic markers including tyrosine hydroxylase (TH), the dopamine transporter (SLC6A3/DAT), and transcription factors LMX1A, PITX3, and FOXA2 that define the midbrain dopaminergic lineage.[2]
iPSC-derived dopaminergic neurons provide a physiologically relevant in vitro model for studying Parkinson's disease (PD) pathogenesis, screening potential therapeutics, and developing cell replacement therapies.[3] These cells can be generated from patients with familial PD mutations (LRRK2 G2019S, SNCA multiplications, GBA) as well as sporadic cases, enabling disease modeling in a patient-specific context.[4]
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000700 | dopaminergic neuron |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:0000700 | dopaminergic neuron | Medium |
The generation of dopaminergic neurons from iPSCs typically follows a directed differentiation approach that mimics embryonic midbrain development:
iPSC-derived dopaminergic neurons are characterized by the following marker expression profile:
| Marker | Type | Function |
|---|---|---|
| TH | Enzyme | Rate-limiting step in dopamine synthesis |
| SLC6A3 (DAT) | Transporter | Dopamine reuptake |
| DDC (AADC) | Enzyme | DOPA decarboxylase |
| LMX1A | Transcription Factor | Midbrain DA neuron specification |
| PITX3 | Transcription Factor | DA neuron survival and maintenance |
| FOXA2 | Transcription Factor | Floor plate identity |
| EN1 | Transcription Factor | Midbrain-hindbrain boundary |
iPSC-derived dopaminergic neurons from PD patients exhibit several pathological features:
These neurons serve as platforms for:
iPSC-derived dopaminergic progenitors are being developed for transplantation therapy in PD:
| Cell Source | Advantages | Limitations |
|---|---|---|
| Primary fetal tissue | Physiologically mature | Ethical concerns, limited supply |
| ESC-derived | Unlimited potential | Tumor risk, immune issues |
| iPSC-derived | Patient-specific, autologous possible | Cost, reprogramming variability |
| Direct reprogramming | Fast, no pluripotent stage | Incomplete maturation |
Kriks et al. 2011 - Dopamine neurons from human embryonic stem cells. 2011. ↩︎
Sonntag et al. 2018 - Pluripotent stem cell-based therapy for Parkinson's disease. 2018. ↩︎
Schumacher et al. 2024 - iPSC models of Parkinson's disease. 2024. ↩︎
Devine et al. 2011 - Parkinson's disease iPSC-derived neurons. 2011. ↩︎
Lu et al. 2009 - α-Synuclein in iPSC-derived neurons from PD patients. 2009. ↩︎
Su et al. 2019 - Mitochondrial dysfunction in PD iPSC neurons. 2019. ↩︎
Schondorf et al. 2018 - iPSC models of GBA-associated PD. 2018. ↩︎
Steger et al. 2020 - LRRK2 inhibitor testing in iPSC neurons. 2020. ↩︎
Takahashi et al. 2023 - Clinical trial of iPSC-derived DA neurons. 2023. ↩︎